Roflumilast Cream for Plaque Psoriasis - An Insight

Overview:Roflumilast cream is used to treat plaque psoriasis efficiently. It is safe and well-tolerated, and it can significantly reduce the severity of psoriasis and relieve itching. On July 29, 2022, the United States Food and Drug Administration approved Roflumilast Cream for plaque psoriasis.

Other than being an option for the treatment of plaque psoriasis, Roflumilast foam is another form of the treatment that provides convenience for those with other conditions, such as seborrheic dermatitis – a skin condition that usually affects the scalp and causes it to become red and scaly.

Drug Group:

The drug group for Roflumilast cream is phosphodiesterase-4 (PDE-4) inhibitors. PDE-4 inhibitors function by blocking the PDE-4 enzyme, which lowers pro-inflammatory immune responses in psoriatic lesions and helps to alleviate psoriasis symptoms.

Dosages:

It is available as a topical cream or ointment.

• Adults and Children Six Years of Age and Older: Apply once daily to the skin's afflicted area if they have plaque psoriasis.

• Children Under Six Years Old: Consult the physician to discuss the appropriate use and dosage.

Missed Dose:

If you miss a Roflumilast dose, take it as soon as you can, along with your next regular dosage. However, if the time for the next dose is near, the dose that was missed does not have to be taken, and the further dosage should be taken according to the schedule. Do not take two doses to cover up for a missing dose since this will only lead to side effects.

Overdose:

Side effects may include severe vomiting, headache, dizziness, or stomach discomfort if one takes an overdose. In case you think that you have taken too much Roflumilast, then you should go get medical help almost instantly. When used for cystic fibrosis, it is important to adhere to the appropriate dose of roflumilast as recommended by your doctor for a safe purpose and the most effective treatment.

For Patients:

What Is Roflumilast Used for?

It is also indicated for the management of plaque psoriasis. This is a long-term skin disorder where patients develop red patches of skin which tend to be covered with silvery scales. It is an inhibitor of phosphodiesterase-4 (PDE4), one of the enzymes involved in inflammation. Thus, it helps to reduce inflammatory skin symptoms associated with the said condition, such as inflammation, redness, and scaling. Roflumilast is considered appropriate for patients with moderate to severe plaque psoriasis, particularly where topical administration is likely to produce an inadequate result. There are creams that can be directly applied to the sites that need treatments, which are in topical form or systemic in the form of tablets that are ingested when the whole body is affected. This management method offers an expectation of efficient control of plaque psoriasis without the use of steroidal products.

How Does Roflumilast Cream Work?

Roflumilast cream is a phosphodiesterase-4 (PDE-4) inhibitor that suppresses the immune system's pro-inflammatory reactions in psoriatic lesions. Psoriatic skin has been shown to exhibit increased PDE4 activity.

Roflumilast mechanism of action is through the inhibition of PDE4. Roflumilast raises intracellular cAMP levels and decreases the expression of inflammatory modulators, including interleukin-17 (IL-17), interleukin-23 (IL-23), interferon-γ, and tumor necrosis factor-alpha (TNF-α), that are linked to psoriatic skin abnormalities. This lessens skin redness, itching, thickness, and plaque formation by suppressing epidermal inflammation and keratinocyte proliferation.

Studies have shown that it significantly improves skin clearance and disease severity in cases of plaque psoriasis. The cream's special composition enables high medication concentrations in the skin, encouraging interactions between the drug and the skin that improve its effectiveness. Roflumilast cream, a safe and non-steroidal substitute for conventional therapies, is a promising once-daily topical treatment for plaque psoriasis.

How Effective Is Roflumilast in Plaque Psoriasis?

Roflumilast cream has proved to be very effective when used in the treatment of plaque psoriasis. They seem most useful in areas such as the face and intertriginous zones, and the adverse effects are kept to the minimum. This makes it a worthwhile prospect for providing additional management to psoriasis-affected patients, who often experience problems in managing their many medications and applications.

What Are the Benefits of Roflumilast?

Roflumilast combines various advantages in the treatment of plaque psoriasis, especially in a moderate to severe form. This drug, a selective phosphodiesterase type 4 (PDE4) antagonist, acts via anti-inflammatory mechanisms and suppression of sustained and over-production of immune mediators that characterize psoriasis. The condition has been shown to cause symptoms such as erythema, silvery scales, and thick hyperkeratotic plaques that reduce the quality of life of affected individuals. Treatment with the intervention has been demonstrated to have beneficial impacts on improving skin health. Another advantage is that the side effects of Roflumilasere are mild to moderate, and the drug is non-steroidal in nature, so it may be used in the long-term management of the disease for individuals who want oral therapy for their condition.

What Must the Patient Inform the Doctor Before Taking Roflumilast Cream for Plaque Psoriasis?

• Monitoring: Doctors need to perform regular check-ups both to assess medication success and to detect any adverse effects. The safety functions of Roflumilast cream result from proper monitoring procedures, which makes the psoriasis treatment effective.

• Condition Status: The doctor must be informed if the psoriasis condition worsens or does not show betterment.

• Medication: Inform the healthcare provider about all the medications you are taking, including over-the-counter pills, prescription medicines, vitamin supplements, or herbal products.

Does Roflumilast Cream Cause Side Effects?

Roflumilast side effects are listed below:

• Gastric disturbances like nausea or diarrhea.

• Headache.

• Sleep disturbances such as insomnia.

• Pain or redness at the site of application.

• Infections such as upper respiratory tract or urinary tract infections.

For Doctors:

Description:

Roflumilast is available as a 0.3 percent topical cream. It is in white to off-white. The active ingredient is Roflumilast, a potent phosphodiesterase 4 (PDE4) inhibitor.

3-cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide is the chemical formula for Roflumilast. C17H14Cl2F2N2O3 is the empirical formula, while 403.21 is the molecular weight. Roflumilast is easily soluble in acetone, sparingly soluble in ethanol, and essentially insoluble in water and hexane.

In a base consisting of ceteareth-10 phosphate, Cetearyl phosphate, cetostearyl alcohol, diethylene glycol monoethyl ether, hexylene glycol, isopropyl palmitate, methylparaben, propylparaben, purified water, sodium hydroxide, and white petrolatum, It is possible that hydrochloric acid was used to alter pH.

Therapeutic Uses of Roflumilast Cream:

The skin condition known as plaque psoriasis, characterized by red areas covered in white scales, is treated with Roflumilast cream. It is effective and tolerable when administered once daily, particularly on delicate areas like the face. In addition, seborrheic dermatitis is treated with it. Seborrheic dermatitis is a skin disorder that mostly affects the scalp and creates red, scaly areas of skin.

Dosage and Administration:

• Once a day, use topical Roflumilast 0.3 percent cream on the plaque psoriasis-affected regions, making sure to apply it evenly.

• Suitable for intertriginous areas.

• In between skin folds for plaque psoriasis.

• Not to be used intravaginally, orally, or topically.

• If hand psoriasis is not treated, wash your hands after applying it.

• Keep the container at room temperature.

Indications:

Roflumilast cream is recommended for the topical treatment of plaque psoriasis in individuals 12 years of age and older, including intertriginous areas.

What Are the Contraindications to Roflumilast?

Roflumilast is contraindicated in plaque psoriasis in patients with moderate to severe hepatic impairment, Child-Pugh C or B, because of metabolism and accumulation. Also, patients with a history of depression with either suicidal thoughts or behavior should be wary, given the fact that this drug is likely to worsen psychiatric symptoms. Roflumilast interactions on rifampin, carbamazepine, or phenobarbital, which are strong CYP3A4 inducers, Roflumilast is less effective due to increased metabolism. It is thus important to give proper attention to the performance of prior medication that the patient takes to avoid the interaction and utilization of roflumilast in the treatment of plaque psoriasis.

Warnings and Precautions:

There are certain crucial cautions and warnings regarding Roflumilast cream to be aware of:

• Liver Disease: If individuals have moderate to severe liver disease, stay away from it.

• Suicidal Ideas: Keep an eye out for any shifts in mood or suicidal ideas.

• Drug Interactions: To prevent drug interactions, tell the physician about all of the prescriptions.

• Allergic Responses: Be under monitoring for indications of allergic responses.

• Appropriate Use: Use only as instructed, avoiding contact with the mouth, nose, eyes, and other sensitive areas.

What Are the Adverse Reactions of Roflumilast Cream?

• Sleep problems (insomnia).

• Pain and burning during urination.

• Headache.

• Cold symptoms like a stuffy nose, sneezing, and sore throat.

What Are the Pharmacological Aspects of Roflumilast Cream?

1. Mechanism of Action:

PDE4 is inhibited by Roflumilast N-oxide, the active metabolite of Roflumilast. Intracellular cyclic AMP builds up when Roflumilast and Roflumilast N-oxide block PDE4, a key enzyme that metabolizes cyclic three ′,5′-adenosine monophosphate (cyclic AMP). It is unclear exactly what mechanisms Roflumilast uses to carry out its medicinal effects.

2. Pharmacokinetics:

After topical treatment, Roflumilast cream has 0.3 percent bioavailability and 1.5 percent bioavailability, which results in high concentrations in the skin relative to plasma levels. Phase III trials evaluated the systemic exposure of Roflumilast and its active metabolite, Roflumilast N-oxide. Following eight weeks of treatment, mean plasma concentrations of Roflumilast were found to be 1.72-1.78 ng/mL(nanograms per milliliters) and Roflumilast N-oxide to be 9.86-10.2 ng/mL. By Day 15, Roflumilast cream concentrations in the skin are significantly higher than those in plasma, as the cream is gradually discharged from the skin and reaches a stable state.

Drug Interactions:

• Fluticasone or Salmeterol.

• Umeclidinium or Vilanterol.

• Aspirin.

• Fluticasone.

• Budesonide.

• Formoterol.

• Glycopyrrolate.

• Apixaban.

• Sacubitril or Valsartan.

• Omega-3 polyunsaturated fatty acids.

• Fluticasone nasal.

• Furosemide.

• Metoprolol.

• Metoprolol tartrate.

• Guaifenesin.

• Esomeprazole.

• Albuterol.

• Pantoprazole.

• Montelukast.

• Tiotropium.

• Budesonide or Formoterol.

• Fluticasone.

• Acetaminophen.

• Albuterol.

• Cyanocobalamin.

• Ascorbic acid.

• Cholecalciferol.

• Salmeterol.

• Alprazolam.

• Cetirizine.

Use in Specific Populations:

Pregnancy: Once applied topically, this medication is absorbed systemically and may expose infants. Clinical evidence and animal research indicate that this medication may harm a developing fetus if given to a pregnant patient. Avoid taking this medication during pregnancy or childbirth.

Lactation: Roflumilast or its metabolites are likely to find their way into human breast milk because they are transferred into the milk of breastfeeding rats in animal investigations. It is best to avoid applying directly to the nipple and to expose a newborn directly afterward.

Pediatrics: It is recommended for the topical treatment of adult and pediatric patients six years of age and older who have plaque psoriasis, including intertriginous regions. It is also recommended for the topical treatment of mild to moderate atopic dermatitis in adults and children above six years of age.

Geriatrics: Research studies have not shown any issues unique to the aged population that would restrict the effectiveness of Roflumilast topical cream and foam. Nonetheless, older people are more susceptible than younger adults to the side effects of this medication.

Clinical Studies:

In clinical trials, Roflumilast cream, a topical PDE-4 inhibitor, demonstrated encouraging outcomes in treating plaque psoriasis. The results of two eight-week phase III trials showed that Roflumilast cream was significantly more effective than the vehicle; in DERMIS-1 and DERMIS-2, respectively, 42.4 percent and 37.5 percent of participants scored "clear" or "almost clear" and saw a 2-point improvement on the Investigator Global Assessment (IGA), compared to 6.1 percent and 6.9 percent in the control groups 1. During the eighth week, 39.1 percent of patients using Roflumilast met the primary efficacy endpoint, while just 6.6 percent of patients in the vehicle group did so. Although the cream is safe and effective, common side effects include headaches, nausea, and diarrhea. Highly effective and non-steroidal, Roflumilast cream is suitable for use on a variety of body parts, including delicate ones.

In a phase 1/2a research, at week 4, Roflumilast cream at 0.5 percent and 0.15 percent dosages showed significant improvements, with 66 to 67 percent improvement from baseline in the Target Plaque Severity Score (TPSS) x Target Plaque Area (TPA). The cream caused mild to moderate adverse effects that were well-tolerated. As early as two weeks, Roflumilast cream was statistically superior to the vehicle. Following topical treatment, Roflumilast cream 0.3 percent had a 1.5 percent bioavailability, with concentrations in the skin being significantly greater than in plasma.

According to clinical trials, at week 8, patients treated with Roflumilast had clear or nearly clear skin in 39.1 percent to 42.4 percent of cases. The control group had clear or almost clear skin in 6.1 to 6.9 percent of cases.

Patients with plaque psoriasis have shown satisfactory results with Roflumilast cream, with clear or almost clear skin being the goal. It is a brand-new topical treatment that is applied once daily. A sizable percentage of patients in the clinical trials met the primary efficacy endpoint, demonstrating the cream's higher performance over the vehicle. For psoriasis, larger and longer trials are required to ascertain the safety and durability of Roflumilast.